Terns Pharmaceuticals (TERN)
TERN · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Liver Diseasesrc
Signal Snapshot
0
Clinical Trials (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis. — Circulation (2026) PMID 42610271
- Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI. — Liver Int (2026) PMID 42576670
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Terns Pharmaceuticals.
Full TERN Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.